Illuccix Patent Expiration

Illuccix is a drug owned by Telix Pharmaceuticals Us Inc. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2035. Details of Illuccix's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027031 Kit for radiolabelling
Jul, 2035

(11 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Illuccix is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Illuccix's family patents as well as insights into ongoing legal events on those patents.

Illuccix's family patents

Illuccix has patent protection in a total of 18 countries. It's US patent count contributes only to 21.3% of its total global patent coverage. Click below to unlock the full patent family tree for Illuccix.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Illuccix's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Illuccix Generics:

There are no approved generic versions for Illuccix as of now.





About Illuccix

Illuccix is a drug owned by Telix Pharmaceuticals Us Inc. It is used for imaging prostate cancer using PET scan with PSMA targeting in men. Illuccix uses Gallium Ga-68 Gozetotide as an active ingredient. Illuccix was launched by Telix in 2021.

Market Authorisation Date:

Illuccix was approved by FDA for market use on 17 December, 2021.

Active Ingredient:

Illuccix uses Gallium Ga-68 Gozetotide as the active ingredient. Check out other Drugs and Companies using Gallium Ga-68 Gozetotide ingredient

Treatment:

Illuccix is used for imaging prostate cancer using PET scan with PSMA targeting in men.

Dosage:

Illuccix is available in powder form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
N/A POWDER Prescription INTRAVENOUS